Skip to main content
. 2018 Feb 1;8:2072. doi: 10.1038/s41598-018-20370-9

Figure 2.

Figure 2

JP4-039 suppresses TBI-induced intestinal differentiation defects. JP4-039 (JP4, 20 mg/kg in F14 emulsion) or vehicle (Ctrl) was given to mice once 24 hr (Day 1) after 9.25 Gy TBI. Intestinal tissues were analyzed at indicated times after TBI. (A) Representative immunofluorescence staining of Mucin2 in the villi. Red, Mucin2; Blue, DAPI. Scale bar = 100 µm. (B) Quantification of Mucin2+ cells in villi and (C) in the crypts from A. (D) Representative immunofluorescence staining of Chromogranin A+ (CgA) cells in the villi. Red, CgA; Blue, DAPI. Scale bar = 100 µm. (E) Quantification of CgA+ cells in the villi and (F) in the crypts from D. (G) Mucosal mRNA expression of Mucin2 and (H) Sucrase lsomaltase. cDNA was synthesized from RNA pooled from 3 mice per group. Expression was normalized to that at Day 0, prior to TBI. (B,C,E,F,G and H) values are Mean ± SEM; n = 3 mice in each group. +++P < 0.001, ++P < 0.01, +P < 0.05, 1-way ANOVA followed by Tukey’s multiple comparisons test. ***P < 0.001, **P < 0.01, vehicle vs. JP4, unpaired 2-tailed Student’s t test.